Electromed (ELMD) | Financial Analysis & Statements
Electromed Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
16.9M
Gross Profit
13.2M
78.15%
Operating Income
2.7M
15.81%
Net Income
2.1M
12.65%
EPS (Diluted)
$0.25
Balance Sheet Metrics
Total Assets
53.8M
Total Liabilities
10.6M
Shareholders Equity
43.2M
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
1.9M
Free Cash Flow
2.4M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Electromed Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 64.0M | 54.7M | 48.1M | 41.7M | 35.8M |
| Cost of Goods Sold | 14.0M | 13.0M | 11.5M | 10.2M | 8.5M |
| Gross Profit | 50.0M | 41.7M | 36.5M | 31.4M | 27.3M |
| Gross Margin % | 78.1% | 76.3% | 76.0% | 75.5% | 76.4% |
| Operating Expenses | |||||
| Research & Development | 996.0K | 656.0K | 916.0K | 1.4M | 1.7M |
| Selling, General & Administrative | 39.3M | 34.5M | 31.6M | 27.1M | 22.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 40.3M | 35.1M | 32.5M | 28.5M | 24.2M |
| Operating Income | 9.7M | 6.6M | 4.0M | 3.0M | 3.1M |
| Operating Margin % | 15.1% | 12.0% | 8.3% | 7.1% | 8.8% |
| Non-Operating Items | |||||
| Interest Income | 624.0K | 455.0K | 78.0K | 25.0K | 27.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | -12.0K |
| Pre-tax Income | 10.3M | 7.0M | 4.1M | 3.0M | 3.2M |
| Income Tax | 2.7M | 1.9M | 920.0K | 692.0K | 805.0K |
| Effective Tax Rate % | 26.7% | 26.8% | 22.5% | 23.1% | 25.4% |
| Net Income | 7.5M | 5.2M | 3.2M | 2.3M | 2.4M |
| Net Margin % | 11.8% | 9.4% | 6.6% | 5.5% | 6.6% |
| Key Metrics | |||||
| EBITDA | 10.8M | 7.4M | 4.6M | 3.6M | 3.8M |
| EPS (Basic) | $0.89 | $0.60 | $0.37 | $0.27 | $0.28 |
| EPS (Diluted) | $0.85 | $0.58 | $0.36 | $0.26 | $0.27 |
| Basic Shares Outstanding | 8454100 | 8562245 | 8463684 | 8471320 | 8566224 |
| Diluted Shares Outstanding | 8454100 | 8562245 | 8463684 | 8471320 | 8566224 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Electromed Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 15.3M | 16.1M | 7.4M | 8.2M | 11.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 24.7M | 23.3M | 24.1M | 21.1M | 17.0M |
| Inventory | 3.3M | 3.7M | 4.2M | 3.2M | 2.1M |
| Other Current Assets | 392.0K | 329.0K | 1.6M | 1.9M | 276.0K |
| Total Current Assets | 45.1M | 44.2M | 37.8M | 34.5M | 31.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.6M | 4.3M | 4.3M | 3.5M | 4.6M |
| Goodwill | 1.3M | 657.0K | 605.0K | 599.0K | 663.0K |
| Intangible Assets | 1.3M | 657.0K | 605.0K | 599.0K | 663.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.5M | 2.2M | 1.6M | 1.5M | 1.1M |
| Total Non-Current Assets | 8.7M | 8.1M | 8.0M | 6.8M | 5.4M |
| Total Assets | 53.8M | 52.2M | 45.8M | 41.4M | 37.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.7M | 1.0M | 1.4M | 1.3M | 685.0K |
| Short-term Debt | - | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 33.0K |
| Total Current Liabilities | 10.5M | 7.7M | 8.1M | 7.2M | 4.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | - | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 125.0K | 12.0K | 86.0K | 41.0K | 54.0K |
| Total Non-Current Liabilities | 125.0K | 12.0K | 86.0K | 41.0K | 54.0K |
| Total Liabilities | 10.6M | 7.7M | 8.1M | 7.2M | 4.7M |
| Equity | |||||
| Common Stock | 83.0K | 87.0K | 86.0K | 85.0K | 85.0K |
| Retained Earnings | 21.2M | 23.7M | 18.8M | 15.8M | 14.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 43.2M | 44.5M | 37.7M | 34.2M | 32.4M |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Working Capital | 34.6M | 36.5M | 29.7M | 27.4M | 27.1M |
Balance Sheet Composition
Electromed Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 7.5M | 5.2M | 3.2M | 2.3M | 2.4M |
| Depreciation & Amortization | 1.2M | 841.0K | 613.0K | 628.0K | 610.0K |
| Stock-Based Compensation | 3.1M | 1.7M | 708.0K | 976.0K | 1.0M |
| Working Capital Changes | 181.0K | 693.0K | -3.6M | -2.5M | -1.3M |
| Operating Cash Flow | 11.6M | 7.8M | 828.0K | 873.0K | 2.4M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | -287.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | -287.0K |
| Financing Activities | |||||
| Share Repurchases | -10.0M | -275.0K | -153.0K | -1.4M | -1.1M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -12.3M | -275.0K | -463.0K | -1.5M | -1.3M |
| Free Cash Flow | 11.1M | 8.7M | -401.0K | -2.2M | 2.6M |
| Net Change in Cash | -639.0K | 7.5M | 365.0K | -652.0K | 824.0K |
Cash Flow Trend
Electromed Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
24.42
Forward P/E
41.23
Price to Book
4.58
Price to Sales
3.05
PEG Ratio
0.56
Profitability Ratios
Profit Margin
13.06%
Operating Margin
19.16%
Return on Equity
20.20%
Return on Assets
13.62%
Financial Health
Current Ratio
4.86
Debt to Equity
0.21
Beta
0.32
Per Share Data
EPS (TTM)
$1.03
Book Value per Share
$5.49
Revenue per Share
$8.24
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ELMD | 212.5M | 24.42 | 4.58 | 20.20% | 13.06% | 0.21 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Monogram | 244.2M | -13.04 | 25.10 | -228.82% | 0.00% | 3.44 |
| Sight Sciences | 237.2M | - | 3.66 | -50.74% | -49.67% | 63.77 |
| Nevro | 224.1M | 144.40 | 0.96 | -43.29% | -27.77% | 108.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.






